

Index

Aachen Aphasia Test (AAT), 441	neuroprotection, 327–28	ICU stroke patients, 357–58
ABCDE scoring systems, 121	recanalization techniques, 315–26	Anderson–Fabry disease. <i>See</i> Fabry disease
ACCESS trial, 378	surgical interventions, 328	andexanet alfa, 226–27
ACCORD trial, 141	Adamantiadis–Behçet’s disease, 260	aneurysmal SAH, 233–34
acenocoumarol, 217	ADAPT (A Direct Aspiration, first Pass Technique), 341	ancillary investigations for diagnosing aneurysms, 236–37
acetaminophen, 382	adhesion molecules, 24	ancillary investigations for diagnosing SAH, 235–36
acetazolamide, 251, 259	adiponectin receptor 1, 22	clinical long-term outcomes, 243–44
acidotoxicity	adrenocorticotrophic hormone (ACTH), 273	definition, 233
role in ischemic injury, 20	aggressive behavior	delayed cerebral ischemia prevention or treatment, 241–43
Action Research Arm Test (ARAT), 78	post-stroke, 274	diagnosis, 234–37
ACTIVE study, 416	agitation	epidemiology, 233–34
activities of daily living (ADLs), 68, 78	as stroke symptom, 188	general management, 240–41
acute febrile neutrophilic dermatosis, 300	AIDS patients, 190, 402, 403, 405	initial assessment, 238–39
acute multifocal placoid pigment epitheliopathy, 297	airway management	long-term outcome, 243–44
acute strokes	intensive care of stroke, 356–57	prevalence of intracranial aneurysms, 233
BP and outcome, 376–77	akinesia	prevention of rebleeding, 243
BP and outcome in thrombolized patients, 377	stroke symptom, 189–90	prognosis, 238
chain of survival and recovery, 307–8	Akt (protein kinase B), 23	risk factors for intracranial aneurysms, 233
controlling BP in the acute stroke phase, 377–79	Alberta Stroke Program Early CT Score (ASPECTS), 50, 69–70, 73, 74, 75, 322	risk of cardiovascular events, 244
emboli monitoring, 100–1	alcohol consumption	risk of new episodes, 244
fast-track neurovascular ultrasound examination, 97–100	risk factor for ICH, 216	symptoms and signs, 234–35
hyperglycemia, 379–80	stroke risk and, 134	treatment, 238–43
hyperglycemia control, 380–81	alexia/agraphia, 264–67	anger
hypertensive BP values, 376	alien-hand syndrome, 171	post-stroke, 274
hyperthermia, 381	alteplase (rtPA), 315–19	angiokeratoma corporis diffusum. <i>See</i> Fabry disease
management of post-stroke complications, 383–88	Alzheimer’s disease, 3, 146, 202	angiotensin-converting enzyme (ACE) inhibitors, 410
management recommendations and guidelines, 382–83	cerebral amyloid angiopathy, 217–18	angiotensin-receptor blocker (ARB), 410
midline shift detection, 104	differential diagnosis, 205–8	animal models of stroke, 9–11
optic nerve sheath diameter (ONSD), 104	differential diagnosis with FDG PET, 208–9	challenge of clinical translation to humans, 26
post-stroke dementia, 387–88	effects of stroke, 282	clot embolism of the MCA, 11
post-stroke depression, 385–87	imaging the accumulation of pathologic proteins, 209–10	filament occlusion of the MCA, 10
post-stroke fatigue, 388	amantadine, 388	quantitative use of PET, 26–27
post-stroke seizures, 383–85	amaurosis fugax, 172	transcranial occlusion of the MCA, 10
prognostic value of ultrasound, 102–3	American Heart Association (AHA) ICH guidelines, 369	transorbital MCA occlusion, 10
promising ancillary ultrasound techniques, 103–4	American Heart Association/American College of Cardiology (AHA/ACC) CV Risk Calculator, 122	ANNEXA-4 study, 227
therapeutic hypothermia, 381–82	American Heart Association/American Stroke Association (AHA/ASA) definition of stroke, 109–10	anterior cerebral artery (ACA), 169
ultrasound detection of arterial resistance, 104	guidelines, 256, 378, 381, 382–83	cognitive effects of strokes, 203
acute therapies, 307	amnesia, 268–70	stroke syndromes, 171
aims of, 315	stroke syndromes which cause, 187–88	anterior choroidal artery (AChA), 169
brain edema, 328	amniotic emboli, 300	stroke syndromes, 171–72
early anti-thrombotic treatment, 326–27	Amsterdam–Nijmegen Everyday Language Test A-scale, 441	anterior circulation
increased intracranial pressure, 328	amyloid deposition	clinical distinction between anterior and posterior circulation strokes, 172–73
intra-arterial thrombolysis, 319	imaging, 209–10	description, 169–70
intravenous thrombolysis, 315–19	analgesia	low-flow stroke syndromes, 182–84
mechanical thrombectomy, 319–24		recanalization of tandem occlusion, 348–49

Index

- anterior inferior cerebellar artery (AICA)
 - stroke syndromes, 174
 - anti-coagulant therapy, 144–45
 - antagonization in ICH, 225
 - atrial fibrillation (AF), 156
 - cerebral venous thrombosis, 257–58
 - ICU stroke patients, 360–61
 - in cerebral ischemia due to cardiac embolism, 415–17
 - in cerebral ischemia of non-cardiac origin, 418–19
 - risk of ICH, 217
- antiemetics, 273
- anti-phospholipid syndrome, 190, 192, 299
- anti-platelet therapy, 417
- ICH in patients with, 225–26
 - role in secondary prevention, 412–15
- anti-thrombotic treatment
- early treatment, 326–27
- anxiety disorders
- post-stroke, 276
- aortic arch
- atherosclerosis, 40
 - dissection, 197
- APASS trial, 419
- apathetic personality change, 277–78
- aphasia, 264–67
- adynamic aphasia, 178
 - functional imaging, 81
 - rehabilitation, 440–41
- aphemia, 170
- apixaban, 144, 145, 156, 226, 415, 416
- potential reversal agents, 226–27
- APOE gene, 11
- ApoE ε4 allele, 218
- ApoE4 genotype, 286
- apoptosis, 8, 21
- activation by damaged mitochondria, 22
 - pathways, 22
 - role in ischemic cell death, 22
 - TUNEL assay, 8
- apoptosis inducing factor (AIF), 22
- APP gene, 11
- apparent diffusion coefficient (ADC) of water, 16
- apraxia (post-stroke), 441–42
- arachidonic acid, 21
- argenin, 21
- ARISTOTLE trial, 416
- Arm Ability Training (AAT), 436
- Arm Basis Training (AAT), 436
- arterial dissection
- unusual presentations, 196–97
- arterial resistance
- ultrasound detection, 104
- arterial spin labeling (ASL), 58
- arteriolosclerosis, 1
- arteriosclerosis, 1
- ASICs (acid-sensing ion channels), 20
- Aspergillus* spp., 190, 398, 404–5
- aspiration pneumonia
- post-stroke, 405–6
- ASPIRE approach, 121
- aspirin, 295, 326–27, 412–15, 416
- AST apraxia screen, 442
- ASTER trial, 345
- asterixis, 46
- ASTRAL model, 70
- ATACH trial, 225
- ATACH II trial, 225, 369
- ataxic hemiparesis, 179
- atenolol, 410
- atheroma, 299
- atheromatous plaques, 1, 2
- atherosclerosis
- aneurysm formation, 2
 - atherosclerotic plaque development, 1–2
 - fatty streak precursor lesions, 1
 - pathological development, 1–2
 - response-to-injury hypothesis, 1–2
 - sites affected, 1
- atherosclerotic plaques
- stages of development, 1–2
- atherosclerotic thromboembolism, 2–3
- ATLANTIS A and B trials, 315
- atorvastatin, 411, 412
- atrial fibrillation (AF)
- cardioembolic stroke risk in non-valvular AF, 42
 - catheter ablation of AF for stroke prevention, 157–58
 - clinical relevance of paroxysmal AF, 155–56
 - definition, 154
 - diagnosing paroxysmal AF, 154–55
 - embolic stroke and, 41
 - in young people and children, 294
 - left atrial appendage occlusion for stroke prevention, 156–57
 - oral anti-coagulant therapy, 156
 - prevalence, 154
 - primary and secondary stroke prevention, 156–58
 - relevance to stroke, 154–58
 - risk factor for stroke, 144–45
 - stroke risk, 154
- atrial natriuretic peptide (ANP), 157
- atrial septal aneurysm (ASA)
- relevance to stroke, 163
- ATTEND trial, 430
- AVERROES trial, 416
- AVERT trial, 426
- Babinski-Nageotte syndrome, 174
- Babinski's sign, 170
- baclofen, 273
- bacterial infections
- stroke syndromes related to, 192–93
- bacterial meningeal infections
- stroke syndromes related to, 192–93
- Balint's syndrome, 177, 180
- BASICS study, 347
- basilar artery (BA), 172
- stroke syndromes, 175–76, 186–87
 - ultrasound diagnosis of stenosis and occlusion, 97
- basilar artery (BA) occlusion
- intensive care, 367
 - recanalization techniques, 347–48
- behavioral neurology of stroke
- amnesia, 268–70
 - anger and aggressiveness, 274
- anxiety disorders, 276
- aphasia, 264–67
- conceptual representation system (semantic system), 264
- delirium, 272–74
- delusions, 274–75
- emotional expression control disorders, 275–76
- executive deficits, 270–71
- hallucinations, 274–75
- language disorders, 264–67
- memory disturbances, 268–70
- neglect, 267–68
- patterns of cognitive deficits, 264
- personality changes, 277–78
- post-stroke depression, 277
- post-stroke mania, 276–77
- post-traumatic stress disorder (PTSD), 276
- prosopagnosia, 272
- psychotic disorders, 274–75
- visual agnosia, 271–72
- Behçet's disease, 1, 190, 297
- Bendikt's syndrome, 46
- benzodiazepine receptor (BZR) ligands, 27
- beta-blockers, 410
- beta thalassemia, 299
- Binswanger's disease, 185, 204
- biochemical imaging
- infarct core and penumbra, 16
- bioprosthesis
- stroke risk, 161
- blind sight, 186
- blindness, bilateral
- stroke syndromes which cause, 186–87
- blood–brain barrier, 13, 21, 24
- blood glucose
- control in ICU stroke patients, 359
 - glucose control and stroke risk, 142
 - hyperglycemia, 379–80
 - hyperglycemia control, 380–81
 - management in stroke patients, 412
 - recommendations and guidelines for acute stroke, 382–83
- blood–oxygen-level-dependent (BOLD) signal, 78
- blood pressure (BP)
- acute stroke outcome and, 376–77
 - anti-hypertensive agents, 141
 - controlling in the acute stroke phase, 377–79
 - elevated BP and stroke risk, 140–41
 - hypertensive BP values in acute ischemic stroke, 376
 - influence on outcome in thrombolized stroke patients, 377
 - management in ICH, 224–25
 - management in ICU stroke patients, 361
 - recommendations and guidelines for acute stroke, 382–83
- Bobath therapy, 436
- body temperature
- hyperthermia, 381
 - management in ICU stroke patients, 361–62

- recommendations and guidelines for
 - acute stroke, 382–83
 - therapeutic hypothermia, 381–82
- borderzone infarcts, 3, 4
 - stroke syndromes, 179–80
- Borrelia afzelii*, 403
- Borrelia burgdorferi*, 403
- Borrelia garinii*, 403
- boundary zone infarcts
 - stroke syndromes, 182–83
- Bradford Hill criteria, 124
- bradycardia
 - causes, 158
 - definition, 158
 - diagnosis, 158
 - practical approach to stroke patients
 - with, 158
 - relevance to stroke, 158–59
 - symptoms, 159
- brain blood supply
 - imaging assessment, 73–75
- brain edema, 6, 13
 - acute therapies, 328
 - complication of ICH, 222
 - cytotoxic edema, 23–24
 - elevated intracranial pressure and, 362–64
 - role in ischemic injury, 23–24
 - vasogenic edema, 23–24
- brain tissue
 - energy requirements, 14
- BRASIL study, 58
- BRAVO trial, 414
- Broca aphasia, 170
- Buerger disease, 297
- bupropion, 133, 134
- CA (Contact Aspiration) technique, 341
- CADASIL, 1, 3, 11, 219, 286
 - in young people and children, 296
 - stroke syndromes related to, 193–94
- CADISS trial, 419
- Cajal, Santiago Ramón y, 9
- calcium-channel blockers, 410
- calcium intake
 - stroke risk and, 138
- calcium toxicity
 - role in ischemic injury, 21
- California score, 121
- Candida* spp., 190, 398
- Capgras syndrome, 274
- CAPRIE trial, 413
- capsular warning syndrome, 186
- CARASIL, 11
- cardiac diseases relevant to stroke
 - atrial fibrillation (AF), 154–58
 - atrial septal aneurysm (ASA), 163
 - bradycardia, 158–59
 - coronary heart disease, 159–60
 - dilated cardiomyopathy, 164
 - endomyocardial fibrosis, 166
 - infective endocarditis, 160–61
 - left ventricular hypertrabeculation (LVHT), 164–66
 - non-compaction (LVHT), 164–66
 - patent foramen ovale (PFO), 162–63
 - QT prolongation, 159
 - relevance in different respects, 154
 - restrictive cardiomyopathy, 164
 - stroke after heart surgery, 161
 - stroke after heart valve repair, 161
 - stroke in patients with bioprosthesis, 161
 - stroke in patients with mechanical valve prosthesis, 161–62
 - tachycardia, 158–59
 - Takotsubo cardiomyopathy, 164
 - valvular heart disease, 160–62
- cardioembolic sources
 - atrial fibrillation (non-valvular), 42
 - classification, 42–43
 - dilated cardiomyopathy, 43
 - endocarditis, 43
 - mitral valve prolapse, 43
 - myocardial infarct, 43
 - patent foramen ovale (PFO), 43
 - prosthetic heart valves, 42–43
- cardioembolic stroke
 - cardioembolic sources, 42–43
 - clinical features, 43–44
 - incidence, 41
 - neuroimaging features, 43–44
 - proportion of all strokes caused by, 41–42
 - role of cardiac disease in stroke, 41
- cardioembolism
 - in young people and children, 294–95
- CARESS trial, 101
- carotid artery
 - anterior circulation, 169
 - Doppler ultrasound evaluation of stenosis, 90–91
 - stenting in stroke patients, 419–20
- carotid endarterectomy
 - in stroke patients, 419–20
- case fatality rates for stroke, 115–16
 - trends, 116–18
- CAST trial, 326
- catheter ablation of AF for stroke
 - prevention, 157–58
- catheter angiography, 333–34
- caudate hemorrhage, 5
- Causative Classification System for Ischemic Stroke (CCS), 39
- causes of ischemic stroke. *See* ischemic stroke causes
- cellular pathology of ischemic injury, 6–9
 - delayed neuronal cell death, 8
 - neurovascular unit pathology, 9
 - primary neuronal cell death, 7–8
- cerebellar hemorrhage, 5
- cerebellar stroke
 - space-occupying stroke, 365–67
- cerebral amyloid angiopathy (CAA), 1, 3, 5
 - ICH associated with, 217–18
- cerebral angiopathy
 - acute reversible angiopathies, 298
 - post-partum, 298
- cerebral autosomal dominant arteriopathy
 - with subcortical infarcts and leukoencephalopathy. *See* CADASIL
- cerebral blood flow
 - autonomic regulation, 11–12
 - disturbances of flow regulation, 12
 - functional and structural viability thresholds of ischemia, 14–16
 - metabolic regulation, 11–12
 - normal blood flow regulation, 11–12
- cerebral perfusion
 - imaging assessment, 73–75
- cerebral salt wasting, 240
- cerebral venous thrombosis (CVT), 6
 - anatomy of the cerebral venous system, 250
- anti-coagulation therapy, 257–58
- aseptic CVT, 250–51
- clinical features, 252
- computed tomography (CT), 253
- cord sign and delta sign in CT, 253
- diagnostic challenge, 250
- diagnostic workup, 252–56
- digital subtraction angiography (DSA), 255
- elevated intracranial pressure, 259–60
- epileptic seizures, 259
- etiology, 250–51
- future developments, 261–62
- in elderly patients, 261
- in neonates, 261
- in pregnancy and puerperium, 260–61
- incidence among stroke patients, 250
- incidence of intracerebral hemorrhage (ICH), 251–52
- laboratory markers, 255–56
- magnetic resonance imaging (MRI), 253–55
- magnetic resonance venography (MRV), 253–55
- nausea treatment, 259
- pain management, 258–59
- pathophysiology, 251–52
- prognosis, 260
- recurrence, 260
- sedation, 259
- septic CVT, 250–51, 252
- symptomatic therapy, 258–60
- therapy, 256–60
- thrombolysis, 258
- treatment of septic CVT, 260
- cerebrovascular diseases (CVD)
 - atherosclerosis, 1–2
 - frequency of different types, 3
 - ICD-11 classification, 1
 - small-vessel disease (SVD), 3
 - thromboembolism, 2–3
 - vascular origin, 1–3
- cervical arteries
 - cervical fibromuscular dysplasia, 296–97
- cervical artery dissection
 - in young people and children, 296
- cervical fibromuscular dysplasia of cervical arteries, 296–97
- CHAD2DS2-VASc score, 144, 155, 156
- Chagas disease
 - cause of embolic stroke, 401
- CHANCE trial, 327, 379, 415
- CHARISMA trial, 413
- Charles Bonnet syndrome, 275
- chemokines, 24

Index

- CHHIPS trial, 378
 chickenpox, 192, 403
Chlamydia pneumoniae, 395–96
 chocolate consumption
 stroke risk and, 139
 cholesterol levels
 ICH risk and, 216–17
 management in stroke patients, 411–12
 stroke risk and elevated cholesterol, 142–44
 chorea, 46
 choriocarcinoma, 300
 chronic obstructive pulmonary disease (COPD), 385
 Churg–Strauss syndrome, 190, 297
 cigarette smoking. *See* smoking
 Cincinnati Prehospital Stroke Scale (CPSS), 307
 CIP-model, 121
 circle of Willis, 13
 Claude's syndrome, 46
 CLEAR III trial, 223
 CLEAR-ICH III trial, 370
 clinical application of experimental results, 26–29
 prediction of irreversible tissue damage, 27
 quantitative use of PET, 26–27
 surrogate markers for irreversible damage, 27–29
 surrogate markers for penumbra, 27–29
 surrogate markers for treatment efficacy, 29
 translating animal models to humans, 26
 clinical assessment
 in the stroke unit, 310
 Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar), 273
 clinical presentations. *See* stroke syndromes
 clinical trials
 patient selection based on multimodal imaging, 60–61
 clopidogrel, 11, 326, 327, 412–15, 416
 CLOSE trial, 163, 417
 CLOSURE trial, 417
 clot embolism of the middle cerebral artery
 animal model, 11
 CLOTBUST trial, 103
 CLOTS trial, 360
 CLOTS3 trial, 360
 clotting cascade, 2
 coagulase-negative staphylococci, 190, 398
 cocaine, 5, 196, 197
Coccidioides immitis, 402
 coccidioidomycosis, 402
 Cockcroft–Gault formula, 156
 coffee consumption
 stroke risk and, 139
 cognition
 neurorehabilitation after stroke, 442
 cognitive assessment tools, 264
 cognitive decline
 recognition in stroke patients, 289
 role of stroke risk factors, 146
 cognitive deficits
 patterns in stroke disorders, 264
 cognitive impairment no dementia, 282
 COL4A1 gene, 11
 collagen disorders, 1
 collateral circulation, 13
 Collier sign, 175
 coma, 258
 as stroke symptom, 188
 complications (post-stroke)
 aspiration pneumonia, 405–6
 diagnostic workup of post-stroke infections, 405
 early-onset infectious complications, 405
 infections, 405–6
 management of, 383–88
 urinary tract infections (UTI), 406
 computed tomography (CT)
 comparison with MRI for acute stroke imaging, 59–60
 cord sign and delta sign in CVT, 253
 CT angiography (CTA), 53–54
 intracranial hemorrhage (ICH), 54
 non-contrast CT (NCCT), 50–51
 perfusion CT (PCT), 51–53
 practical aspects of acute stroke CT, 50
 spot sign, 218–19
 structural imaging, 69–71
 computed tomography angiography (CTA), 53–54
 conceptual representation system, 264
 conduction aphasia, 171
 Confusion Assessment Method, 273
 congenital thrombophilia, 6
 connective tissue disease
 stroke syndromes related to, 190–92
 constraint-induced movement therapy (CIMT), 435–36
 continuous positive airway pressure (CPAP), 145
 Copenhagen stroke study, 381
 coronary heart disease
 coexistence with stroke, 159
 diagnosis in stroke patients, 159–60
 myocardial infarction as cause of embolism, 160
 relevance to stroke, 159–60
 corticobasal degeneration
 differential diagnosis, 209
 COSSACS study, 378
 COX-2 inhibitors, 24
 cranial nerve palsies, 46
 stroke syndromes associated with, 189
 CREST trial, 420
 Crohn disease, 297
 crying
 uncontrollable, 275–76
 cryptococcal meningitis, 402
Cryptococcus neoformans, 402
 cryptogenic ischemic stroke, 46–47
 Cushing's triad, 174
 cytochrome C, 22
 cytokines, 24
 cytomegalovirus, 395
 dabigatran, 11, 144, 145, 156, 226, 415, 416
 potential reversal agents, 226–27
 dabigatran etexilate, 156
 damage-associated molecular pattern molecules (DMPs), 24
 DASH diet, 137–38, 139
 DASH trial, 137
 DAWN trial, 52, 58, 61, 323–24
 DECIMAL study, 328
 decompressive occipital trepanation (DOT), 367
 DEDAS trial, 29, 318
 deep perforating artery system, 170
 deep vein thrombosis (DVT) prophylaxis, 360
 DEFUSE trial, 29, 58, 75
 DEFUSE-1 trial, 60
 DEFUSE-2 trial, 58, 60
 DEFUSE-3 trial, 52, 58, 61
 Déjerine–Roussy pain syndrome, 178
 Déjerine syndrome, 173, 174
 delayed cerebral ischemia (DCI)
 prevention or treatment, 241–43
 delirium, 272–74
 as stroke symptom, 188
 Delirium Rating Scale, 273
 delusions, 274–75
 dementia
 relationship with stroke, 282
 stroke therapy and stroke prevention, 289
 dementia (post-stroke), 387–88
 causes, 287–88
 definition, 282
 definition of vascular dementia, 282
 demographic predictors, 285
 determinants of, 285
 epidemiology, 283–86
 functional outcome, 288–89
 importance of recognizing dementia in stroke patients, 289
 influence on stroke outcome, 288–89
 literature search, 283
 medical risk factors, 285–86
 mortality related to, 288
 prevalence of dementia in stroke survivors, 283
 relative risk of dementia after stroke, 283–85
 risk related to pre-existing silent infarcts, 286
 risk related to stroke characteristics, 286–87
 stroke recurrence and, 288
 stroke therapy and stroke prevention, 289
 treatments, 289
 types of dementia, 287–88
 dementia with Lewy bodies (DLB), 202
 differential diagnosis with FDG PET, 208–9
 depression (post-stroke), 277, 172–78
 depressive disorders
 differential diagnosis for dementia, 209
 DEPTH-SOS trial, 365
 desmoteplase, 318–19
 DESTINY study, 328
 DESTINY II study, 328, 365
 DESTRO study, 386
 diabetes mellitus
 management in stroke patients, 412
 stroke risk and, 142

- DIAS trials, 29, 61, 318–19
diaschisis, 81
dietary factors
 stroke risk and, 136–39
diffusion kurtosis imaging (DKI), 16
diffusion-weighted imaging (DWI), 16, 54–56
 PWI/DWI mismatch, 58
PWI/DWI mismatch studies, 27–29, 29
digital subtraction angiography (DSA), 333–34
 cerebral venous thrombosis, 255
 indications for, 333
dilated cardiomyopathy
 cardioembolic stroke risk, 43
 relevance to stroke, 164
dipyridamole, 326
dipyridamole, extended-release, 412–15
disability-adjusted life years (DALYs), 68
 stroke disease burden expressed as, 110–11
disseminated intravascular coagulation, 299
distal thrombectomy devices, 336–38
DNA
 fragmentation by ROS, 21
Doppler ultrasound
 evaluation of carotid artery stenosis, 90–91
dorsolateral medullary stroke. *See* Wallenberg syndrome
drop attacks, 184
DSM-4, 387
Dubois, Jacques, 170
dynamic susceptibility contrast (DSC)-PWI, 57
dysarthria-clumsy hand syndrome, 179
dyslexia/dysgraphia, 264–67
dyslipidemia
 stroke risk and, 142–44
dysphagia management, 358–59
dystonia, 46

Eales disease, 297
ECASS trial, 315, 316
ECASS II trial, 315, 316
ECASS III trial, 315, 316
eclampsia, 298–99
edema. *See* brain edema
edoxaban, 144, 145, 156, 226, 415, 416
 potential reversal agents, 226–27
Ehlers Danlos syndrome, 196
EKOS system, 336
elastic tissue disorder, 297
elderly patients
 cerebral venous thrombosis (CVT), 261
electrical stimulation, 436–37
electromechanical-assisted arm training, 437–38
electromechanical-assisted gait training, 432–34
electronic health records (EHRs)
 use in stroke risk prediction, 124
emboli
 amniotic emboli, 300
 fat emboli, 300
 gas emboli, 300
 myocardial infarction as cause of, 160
 non-cruoric emboli in young people and children, 300
 ultrasound monitoring in acute stroke, 100–1
embolic stroke of undetermined source (ESUS), 47
emotional expression control disorders, 275–76
empagliflozin, 412
ENCHANTED study, 377
endocarditis. *See also* infective endocarditis
 cardioembolic stroke risk, 43
 stroke syndromes related to, 190
endomyocardial fibrosis
 relevance to stroke, 166
endoplasmic reticulum (ER), 8, 21
 unfolded protein response (UPR), 21
endoplasmic reticulum (ER)-associated degradation (ERAD), 22
endoplasmic reticulum (ER) overload response (EOR), 23
endoplasmic reticulum (ER) stress response, 21, 23
 inhibition of protein synthesis, 21–22
 role in ischemic injury, 21–22
ENDOSTROKE study, 347
endovascular lymphoma, 299
energy requirements of brain tissue, 14
ENGAGE-AF trial, 416
ENOS trial, 379
Enterobacteriaceae, 398, 404
Enterococcus spp., 190, 398, 399, 404
EPAR system, 336
epidemiology of stroke
 case fatality, 111, 115–16
 definition of stroke, 109–10
 global burden of disease, 110–11
 incidence, 111, 112–13
 measures of occurrence, 111
 mortality, 111–12
 prevalence, 111, 113–15
 subtypes of stroke, 110
 trends in event rates, case fatality, and mortality, 116–18
epilepsy (post-stroke)
 in young patients, 302
 management, 383–85
epileptic seizures
 cerebral venous thrombosis, 259
EPITHET trial, 29, 58, 60
eprosartan, 411
erythrocytosis, 185
erythropoietin (EPO), 23
ESC trial, 419
ESCAPE trial, 54, 61, 345
Escherichia coli, 398
escitalopram, 386
ESPRIT trial, 414, 419
ESPS2 trial, 413
estradiol, 140
estrogen replacement therapy
 stroke risk and, 139–40
ethnic risk factors for stroke, 119
European Atrial Fibrillation Trial, 415
European Federation of Neurological Societies
 guidelines, 95, 256
European Society for Minimal Invasive Neurological Therapy (ESMINT), 349
European Society of Neuroradiology (ESNR), 349
European Stroke Organisation (ESO)
 acute stroke chain of survival and recovery, 307–8
 acute stroke diagnostic workup, 310–11
 facilities necessary for stroke units, 309
 guidelines, 378, 382–83
 ICH guidelines, 369
 ischemic stroke and TIA management guidelines, 311
 mechanical thrombectomy guidelines, 322–23
EVA3S study, 420
EVEREST trial, 430
excitotoxicity
 role in ischemic injury, 20–21
executive deficits, 270–71
EXTEND IA trial, 52, 61, 345
EXTEND IA TNK trial, 52
extracellular signal-regulated kinase (ERK), 23

F-MISO (¹⁸F nitromidazol), 16
Fabry disease, 3, 11
 in young people and children, 299
 stroke syndromes related to, 194–95
Face-Arm-Speech-Test (FAST), 307
facial lentiginosis, 295
familial risk factors for stroke, 119
Fas receptor, 22
fast-track neurovascular ultrasound examination, 97–100
fat emboli, 300
fatigue (post-stroke), 388
ferroptosis, 8
fiberoptic endoscopic evaluation of swallowing (FEES), 358
fibrocalcific lesions, 2
fibromuscular dysplasia, 1, 196, 197
Finnish Diabetes Risk Score (FINDRISC), 122
fish consumption
 stroke risk and, 136–37
FLAIR imaging, 54–56, 58, 59
flat panel detector (FPD) technology, 334
flumazenil, 16
 use in prediction of irreversible tissue damage, 27
focal paresis
 stroke symptom, 190
FOP-ASIA study, 295
Framingham Stroke Profile (FSP), 122
Framingham stroke risk algorithm, 122
Framingham study
 frequency of different types of stroke, 3
 infarct type and dementia risk, 287
 location of stroke lesions, 9
 risk of dementia after stroke, 285
 stroke risk after quitting smoking, 133
 vascular risk and cognitive decline, 146

Index

- free-floating thrombus
 - ultrasound identification, 95
- free radicals. *See* reactive oxygen species (ROS)
- Fregoli syndrome, 274
- frontotemporal dementia
 - differential diagnosis with FDG PET, 208–9
- fruit intake
 - stroke risk and, 136
- Fugl-Meyer score, 71
- functional imaging, 75–83
 - functional and activation studies using PET, 76–78
 - functional magnetic resonance imaging (fMRI), 78
 - neglect, 83
 - post-stroke aphasia, 81
 - recovery from motor deficits, 78–79
 - recovery from somatosensory deficits, 78–79
 - repetitive transcranial magnetic stimulation (rTMS) with activated imaging, 81–83
 - role in stroke patients, 75–76
- functional magnetic resonance imaging (fMRI), 78
- furosemide, 259
- GABA receptors, 27
- GAIN study, 376
- GAMES trial, 363
- gas emboli, 300
- gastric ulcer prophylaxis, 358
- genetic factors
 - monogenic stroke syndromes, 11
 - risk factors for stroke, 119
 - spontaneous ICH, 216
 - stroke, 11
- genome-wide association studies (GWAS), 11
- giant cell arteritis, 1, 192
- GIST-UK trial, 380, 381
- Glasgow Coma Scale, 238
- Global Burden of Disease (GBD) study, 130
- Global Burden of Disease Stroke Panel Experts Group, 111, 113, 114, 116
- global cerebral atrophy, 286
- glucose control. *See* blood glucose
- glutamate
 - role in excitotoxic cell death, 20–21
- glutamate antagonists, 20
 - treatment of focal ischemia, 21
- glycerol, 328
- Golden Hour concept, 25
- Gosling's pulsatility index, 104
- granulomatous angiitis of the CNS, 1
- GRASP trial, 380, 381
- gugging-swallowing-test (GUSS), 358
- Haemophilus influenzae*, 406
- hallucinations, 274–75
- halothane, 23
- HAMLET trial, 328
- HDAC9 gene, 11
- Health Professionals Follow-up Study, 130
- heart valve repair
 - stroke risk, 161
- heart valve surgery
 - stroke risk, 161
- Held-Test, 431
- Helicobacter pylori*, 395, 396
- HELLP syndrome, 298
- hematological disease
 - in young people and children, 299
- hematoma expansion in ICH, 222
- hemibalismus, 46
- hemichorea-hemiballism, 190
- hemimedullary stroke, 174
- hemodynamic reserve, 12
- hemodynamics of stroke
 - autonomic regulation of cerebral blood flow, 11–12
 - collateral circulation, 13
 - effects of microcirculatory disturbances, 12–13
 - false autoregulation, 12
 - flow regulation disturbances, 12
 - metabolic regulation of cerebral blood flow, 11–12
 - normal cerebral blood flow regulation, 11–12
- hemoglobin control
 - ICU stroke patients, 359–60
- hemoglobinopathies, 185, 299
- hemorrhagic infarcts, 4–5
- heparin, 327
 - ICH in patients with heparin therapy, 225–26
 - use in CVT, 6
- hereditary causes of stroke, 193–95
- HERMES meta-analysis, 320–22, 325
- HERNS syndrome, 300
- herpes simplex virus, 395
- herpes zoster (shingles), 403
- Heubner's network, 13
- HIV infection
 - stroke risk, 301
 - vasculopathy and vasculitis associated with, 404
- homocystinuria, 299
- HOPE study, 410
- HOPE-2 study, 412
- HOPE-3 trial, 141
- horizontal gaze palsy, 46
- hormone replacement therapy after menopause
 - stroke risk and, 139–40, 412
- Horner's syndrome, 173, 174
- HPS (Heart Protection Study), 411
- Hsp70 stress protein expression, 16, 22
- HTRA1 gene, 11
- Hughlings Jackson, John, 430
- Hunt and Hess scale, 238
- Huntington's chorea
 - differential diagnosis, 209
- hyaline
 - subendothelial accumulation, 3
- hydrocephalus, 235, 239
- hyperdense middle cerebral artery sign (HMCAS), 336
- hypereosinophilic syndrome, 299
- hyperglycemia. *See* blood glucose
- hyperleukotic leukemias, 185
- hypertension, 6
 - anti-hypertensive agents, 141
 - risk factor for ICH, 216
 - stroke risk, 140–41
 - treatment in stroke patients, 410–11
- hyperthermia, 381
- hyperviscosity
 - low flow and, 185
- hyperviscosity syndromes, 299
- hypoglycemia. *See* blood glucose
- hyponatraemia, 240
- hypothermia
 - therapeutic, 381–82
- hypoxia-inducible factor 1 (HIF-1), 23
- HYVET trial, 141
- ICARE trial, 430
- idarucizumab
 - reversal of dabigatran, 226, 227
- illicit drugs
 - ICH risk, 217
- image-guided interventional therapy
 - aspiration and/or stent retriever thrombectomy, 345
 - catheter angiography, 333–34
 - digital subtraction angiography (DSA), 333–34
 - distal branch occlusion, 349
 - flat panel detector (FPD) technology, 334
 - importance of recanalization in acute stroke, 333
 - posterior circulation, 347–48
 - proximal thrombectomy, 339–42
 - special techniques for particular situations, 347–49
 - standards of practice and training curriculum, 349–51
 - stent retrievers, 342–45
 - tandem occlusion of the anterior circulation, 348–49
 - thromboaspiration, 339–42
- imaging. *See also* multimodal imaging and specific imaging modalities
 - assessment of brain blood supply, 73–75
 - assessment of cerebral perfusion, 73–75
 - functional imaging, 75–83
 - ischemic penumbra, 16
 - post-stroke aphasia, 81
 - recovery from motor and somatosensory deficits, 78–79
 - role in predicting stroke outcome, 68
 - role of functional imaging in stroke patients, 75–76
 - structural imaging, 69–73
- impairment oriented therapy (IOT), 436
- IMS III trial, 337
- INCH trial, 226
- incidence of stroke
 - national differences, 112–13
 - trends, 116–18
- indapamide, 411
- infarcts
 - phases of temporal evolution, 16–19
- infection control in the ICU, 361

- infectious diseases
 - associations with strokes, 395
 - causes of stroke, 396–403
 - causes of vasculitis, 403–4
 - chronic infections and stroke, 395–96
 - chronic infectious burden hypothesis, 396
 - complications of stroke, 405–6
 - infections preceding stroke, 395–96
 - mycotic aneurysms as cause of stroke, 404–5
 - recent infection and stroke, 395
 - with similarities to stroke, 405
- infective endocarditis
 - causes, 396
 - clinical presentation, 398
 - description, 396
 - diagnosis, 160
 - diagnostic criteria, 398
 - in young people and children, 294
 - incidence, 396
 - ischemic stroke associated with, 367–68
 - microbiology, 396–98
 - pathogenesis, 398–400
 - pathogenic mechanisms leading to stroke, 400
 - relevance to stroke, 160–61
 - risk factors, 396
 - stroke risk factors, 160
 - stroke syndromes related to, 190
 - therapy, 160–61, 400–1
- inferolateral arteries
 - stroke syndromes, 178
- inflammation
 - modulator of ischemic injury, 24
- inflammatory response, 21
- inflammatory vasculopathies
 - stroke syndromes related to, 190–92
- insulin resistance
 - management in stroke patients, 412
- INSULINFARCT study, 380
- intensive care of stroke, 355
 - airway management, 356–57
 - analgesia, 357–58
 - anti-coagulation, 360–61
 - basilar artery (BA) occlusion, 367
 - blood pressure (BP) management, 361
 - body temperature management, 361–62
 - brain edema and raised ICP, 362–64
 - conservative management of large or progressive ICH, 368–69
 - deep vein thrombosis (DVT) prophylaxis, 360
 - definition of severe stroke, 355
 - dysphagia management, 358–59
 - feeding and swallowing problems, 358–59
 - fluid status, 359
 - general principles, 355–64
 - glucose control, 359
 - hemoglobin control, 359–60
 - indications for transfer of stroke patients to the NCCU, 355–56
 - infection control, 361
 - intraventricular hemorrhage (IVH) in ICH, 370
 - ischemic stroke from infective endocarditis, 367–68
 - large hemispheric stroke (LHI), 365
 - nutrition, 359
 - peri-interventional care in stroke
 - thrombectomy, 364–65
 - sedation, 357–58
 - seizures, 362
 - space-occupying cerebellar stroke, 365–67
 - specific care for intracerebral hemorrhage (ICH), 368–70
 - specific intensive care for acute ischemic stroke, 364–68
 - surgical management of ICH, 369–70
 - tracheostomy, 357
 - ventilation, 357
- Inter99 trial, 136
- INTERACT study, 224
- INTERACT-2 study, 224, 368–69
- interatrioseptal aneurysm (IASA)
 - association with PFO in stroke patients, 295
 - in young people and children, 295
- internal carotid artery (ICA)
 - stroke syndromes, 172
 - ultrasound identification and classification of stenosis, 91–94
- International Classification of Diseases and Related Health Problems (ICD-11)
 - cerebrovascular diseases (CVD), 1
- international classification of functioning (ICF), 428
- internuclear ophthalmoplegia, 46
- INTERSTROKE study, 116, 119, 130, 140
- intra-arterial thrombolysis, 319
 - pharmacological, 334–35
- intracardiac myxoma
 - in young people and children, 295
- intracerebral hemorrhage (ICH), 5–6
 - alcohol consumption risk factor, 216
 - associated with cerebral amyloid angiopathy (CAA), 217–18
 - blood pressure management, 224–25
 - caudate hemorrhage, 5
 - cerebellar hemorrhage, 5
 - characteristics of, 213
 - cholesterol levels and, 216–17
 - classification systems, 213–14
 - clinical syndromes, 220–21
 - complications, 222
 - conservative management of large or progressive ICH, 368–69
 - development in SVD, 217
 - edema complication, 222
 - effects of antagonization of anti-coagulation, 225
 - epidemiology, 213
 - etiology, 213–14
 - genetics of spontaneous ICH, 216
 - hematoma expansion, 222
 - hemostatic approach, 225
 - hypertension risk factor, 216
 - illicit drugs and, 217
 - imaging
 - choice of modality, 218
 - computed tomography (CT), 54
 - microbleeds, 219–20
 - spot sign on CT, 218–19
 - susceptibility-weighted imaging (SWI), 58–59
 - in patients with anti-platelet therapy, 225–26
 - in patients with heparin therapy, 225–26
 - incidence, 213
 - incidence in cerebral venous thrombosis, 251–52
 - intraventricular hemorrhage (IVH)
 - complication, 222
 - lobar (white matter) hemorrhage, 5
 - mortality, 214–16
 - NOAC-associated ICH, 226–27
 - non-surgical approach, 224–25
 - oral anti-coagulation risk factor, 217
 - pathophysiology, 217–18
 - pontine hemorrhage, 5–6
 - prognostic factors, 214–16
 - putaminal hemorrhage, 5
 - risk factors, 216–17
 - smoking risk factor, 216
 - specific care in the ICU, 368–70
 - spontaneous ICH (SICH), 213
 - statins and, 216–17
 - surgical interventions, 222–24
 - surgical management, 369–70
 - thalamic hemorrhage, 5
 - therapeutic options, 222–25
 - vitamin K antagonist (VKA)-associated ICH, 226
- intracranial aneurysms
 - prevalence, 233
 - risk factors, 233
- intracranial arteries
 - ischemia caused by unruptured aneurysms, 299
- intracranial dissection
 - in young people and children, 297
- intracranial hemorrhage (ICH). *See* intracerebral hemorrhage (ICH)
- intracranial occlusion
 - ultrasound diagnosis, 95–96
- intracranial pressure, elevated, 311–12
 - acute therapies, 328
 - brain edema and, 362–64
- intracranial stenosis
 - treatment in stroke patients, 420–21
 - ultrasound diagnosis, 95–96
- intraocular hemorrhages, 235
- intravenous thrombolysis, 315–19
- intraventricular hemorrhage (IVH), 239
 - complication of ICH, 222
 - intensive care, 370
- inverse steal phenomena, 13
- involuntary movement
 - stroke symptom, 189–90
- ipratropium bromide, 273
- IQCODE questionnaire, 385
- iron-deficiency anemia, 299
- irreversible damage
 - prediction of, 27
 - surrogate markers for, 27–29

Index

- ischemia
 - collateral circulation, 13
 - delayed post-ischemic hypoperfusion, 12
 - disturbances in blood flow regulation, 12
 - effects of microcirculatory disturbances, 12–13
 - effects of tissue acidosis, 12
 - functional and structural viability thresholds, 14–16
 - hemodynamic reserve and, 12
 - post-ischemic hyperemia (luxury perfusion), 12
 - steal and inverse steal phenomena, 12, 13
- ischemic injury
 - acidotoxicity, 20
 - apoptosis, 22
 - calcium toxicity, 21
 - cellular pathology, 6–9
 - cytotoxic and vasogenic edema, 23–24
 - delayed neuronal cell death, 8
 - effects of mitochondrial disturbances, 22
 - effects of the ER stress response, 21–22
 - endoplasmic reticulum (ER) stress response, 21–22
 - excitotoxicity, 20–21
 - Golden Hour concept, 25
 - improving ischemia tolerance of brain tissue, 23
 - mechanisms of infarct progression, 19–23
 - modulation by inflammatory reactions, 24
 - molecular injury cascades, 20–22
 - neuroprotective techniques, 23
 - neurovascular unit pathology, 9
 - nitric oxide (NO) toxicity, 21
 - peri-infarct spreading depression, 19–20
 - pre- and post-conditioning of ischemia, 23
 - primary neuronal cell death, 7–8
 - reactive oxygen species (ROS), 21
 - secondary complications, 23–24
 - sensitivity of different types of brain cell, 6
 - temporal evolution of strokes, 16–19
 - therapeutic window, 24–26
 - zinc toxicity, 21
- ischemic penumbra
 - biochemical imaging, 16
 - concept, 13–14
 - functional and structural viability thresholds, 14–16
 - imaging techniques, 16
 - misery perfusion in animal models, 26–27
 - PWI/DWI mismatch, 58
 - surrogate markers for, 27–29
- ischemic stroke causes
 - cardioembolic stroke, 41–44
 - Causative Classification System for Ischemic Stroke (CCS), 39
 - cryptogenic ischemic stroke, 46–47
 - large artery atherosclerosis, 38–41
 - multiple overlapping causes, 46
 - small-vessel disease (SVD), 44–46
 - TOAST classification, 38
- ischemic strokes
 - borderzone infarcts, 3, 4
 - classification by pathologic mechanism, 38
 - hemorrhagic infarcts, 4–5
 - lacunar infarcts, 3–4, 4
 - low-flow infarcts, 3, 4
 - red (hemorrhagic) infarcts, 4–5
 - territorial infarcts, 3, 4
 - ISCVT trial, 257, 258, 260, 261
 - isoflurane, 23
 - IST trial, 326, 327
 - IST-3 trial, 315, 316
 - JAK/STAT pathway, 24
 - jerky dystonic unsteady hand syndrome, 178
 - Kawasaki syndrome, 300
 - Klebsiella pneumoniae*, 398
 - Köhlmeier-Degos disease, 297
 - Korsakoff syndrome, 178
 - lacunar infarcts, 3–4, 4, 44–45
 - classic lacunar syndromes, 45
 - clinical features, 45–46
 - in young people and children, 296
 - prevalence, 45
 - risk factors, 45
 - silent lacunar infarcts, 46
 - specificity of the clinical lacunar syndromes, 46
 - lacunar stroke syndromes, 3–4, 179
 - language disorders, 264–67
 - confrontation naming tests, 264–65
 - speech fluency testing, 265
 - verbal comprehension testing, 265
 - word repetition testing, 265
 - large artery atherosclerosis
 - aortic arch, 40
 - cause of ischemia, 38–39
 - clinical features, 41
 - mechanisms of cerebral ischemia, 40–41
 - prevalence (extra- and intracranial), 39–40
 - large artery disease
 - in young people and children, 296–99
 - large hemispheric stroke (LHI), 365
 - large-vessel atherosclerosis
 - in young people, 294
 - large-vessel stroke, 202
 - lasofoxifene, 140
 - laughter
 - pathological, 175
 - uncontrolled, 275–76
 - left atrial appendage
 - occlusion for stroke prevention in AF, 156–57
 - left ventricular hypertrabeculation (LVHT)
 - relevance to stroke, 164–66
 - lenticulostriate arteries, 171
 - leptomeningeal artery system, 169
 - leukemia, 299
 - leukoaraiosis, 204, 286
 - Libman-Sachs endocarditis, 299
 - LIFE trial, 136
 - lifestyle factors in stroke risk, 130–39
 - limb-shaking TIA, 172, 183
 - Lipman-Sacks endocarditis, 190
 - lipohyalinosis, 3, 5, 179, 217
 - of the deep perforators in young people, 296
 - liposuction surgery
 - fat emboli, 300
 - lobar (white matter) hemorrhage, 5
 - locked-in syndrome, 175
 - Look AHEAD trial, 135, 142
 - Los Angeles Prehospital Stroke Screen (LAPSS), 307
 - low flow
 - hyperviscosity and, 185
 - stroke syndromes caused by, 182–85
 - low-flow infarcts, 3, 4
 - LUCAS-IVH-trial, 223
 - lues, 1
 - Lyme disease, 403
 - Maeda syndrome, 11
 - magnesium intake
 - stroke risk and, 138
 - magnetic resonance angiography (MRA), 56–57
 - magnetic resonance imaging (MRI)
 - comparison with CT for acute stroke imaging, 59–60
 - contraindications, 54
 - diffusion-weighted imaging (DWI), 54–56
 - FLAIR imaging, 54–56
 - imaging ischemic penumbra, 16
 - multimodal imaging in stroke patients, 54
 - perfusion-weighted imaging (PWI), 57–58
 - practical aspects of acute stroke MRI, 54
 - PWI/DWI mismatch concept, 58
 - PWI/DWI mismatch studies, 27–29, 29
 - structural imaging, 71–73
 - susceptibility-weighted imaging (SWI) and ICH, 58–59
 - malaria
 - ischemic lesions mimicking stroke, 405
 - malignant atrophic papulosis, 297
 - malignant MCA infarction (MMI), 365
 - mania
 - post-stroke, 276–77
 - mannitol, 328
 - MAP kinase, 23
 - MAP kinase pathway, 21
 - Marchiafava-Micheli disease, 299
 - Marfan syndrome, 196
 - MAT (Manual Aspiration Thrombectomy), 341
 - MATCH study, 413
 - mechanical thrombectomy, 319–24
 - mechanical valve prosthesis stroke risk, 162
 - medial medullary stroke, 173
 - medial temporal lobe atrophy (MTLA), 286
 - Mediterranean diet, 139
 - MELAS, 11, 300
 - stroke syndromes related to, 195
 - Melbourne Ambulance Stroke Screen (MASS), 307

- MELT study, 335, 336
 memory disturbances, 268–70
 meningeal infections
 stroke syndromes related to, 192–93
 meningitis
 acute bacterial meningitis, 401–2
 causes of stroke, 401–2
 chronic meningitis, 402
 MERCI Retrieval system, 337
 MERCI trials, 337
 metabolic disorders
 in young people and children, 299–300
 microbial surface components recognizing
 adhesive matrix molecules
 (MSCRAMM), 399
 microbleeds
 dementia risk and, 286
 imaging, 219–20
 microcirculatory disturbances
 role in ischemic brain injury, 12–13
 microembolic signs (MES)
 ultrasound monitoring, 100–1
 microhemorrhages, 203
 imaging, 204–5
 microscopic polyangiitis, 190
 middle cerebral artery (MCA), 169
 animal model of clot embolism, 11
 animal model of filament occlusion, 10
 animal model of transcranial occlusion,
 10
 animal model of transorbital occlusion,
 10
 cognitive effects of strokes, 203
 stroke syndromes, 170–71
 ultrasound diagnosis of occlusion, 96
 ultrasound diagnosis of stenosis, 96
 ultrasound real-time visualization of
 infarction, 101–2
 midline shift
 ultrasound detection, 104
 migraine, 196
 leukoaraiosis, 204
 stroke risk, 301
 stroke syndromes related to, 197–98
 migrainous stroke, 197–98
 mild cognitive impairment (MCI), 208,
 209, 210
 post-stroke, 288–89
 miliary aneurysms, 3
 Miller Fisher, C., 44, 217
 Million Women Study (UK), 119
 Mini Mental State Examination (MMSE),
 264, 275
 mirror therapy, 436
 misery perfusion
 ischemic penumbra in animal models,
 26–27
 MISTIE trial, 223
 MISTIE III trial, 224
 mitochondria
 disturbances caused by ROS, 21
 effects of disturbances induced by
 ischemia, 22
 zinc toxicity, 21
 mitochondrial encephalopathy lactic
 acidosis and stroke. *See* MELAS
 mitochondrial permeability transition
 (MPT), 22
 mitral valve prolapse
 cardioembolic stroke risk, 43
 in young people and children, 295
 MMP12 gene, 11
 modafinil, 388
 Modified Ashworth Scale (MAS), 430–31
 Modified Tardieu Scale (MTS), 431
 molecular mechanisms of ischemic injury
 progression, 20–22
 MONICA Stroke Study, 116, 119–20
 Moniz, Edgaz, 333
 Mönkeberg's sclerosis, 1
 Montreal Cognitive Assessment, 264
 mortality rates for stroke
 influence of post-stroke dementia, 288
 national differences, 111–12
 trends, 116–18
 Moschowitz syndrome, 299
 MOSES trial, 411
 motor deficits
 functional imaging of recovery, 78–79
 Moyamoya, 1, 185
 in young people and children, 297
 stroke syndromes related to, 197
 MR CLEAN trial, 320, 324, 345
 MR RESCUE trial, 60, 337–38
 multimodal imaging
 MRI compared with CT for acute stroke
 imaging, 59–60
 patient selection for clinical trials based
 on, 60–61
 treatment decisions based on, 60
 multi-photon laser scanning microscopy
 (MPM), 6
Mycobacterium africanum, 402
Mycobacterium bovis, 402
Mycobacterium tuberculosis, 402
Mycobacterium tuberculosis complex, 402
 mycotic aneurysms
 as cause of cerebral hemorrhage, 190
 as cause of stroke, 404–5
 myocardial infarction
 as cause of embolism, 160
 cardioembolic stroke risk, 43
 NASCET method of measuring a stenosis,
 93
 NASCET trial, 419
 nasogastric tube (NGT), 358
 National Institutes of Health Stroke Scale
 (NIHSS), 53, 68, 69, 70, 71, 73, 75,
 310, 355, 379
 National Institutes of Health Stroke Score
 (NIHSS), 69
 necrosis, 8
 neglect
 behavioral neurology, 267–68
 functional imaging, 83
 rehabilitation after stroke, 442
 neonates
 cerebral venous thrombosis (CVT), 261
 neuroborreliosis, 402–3
 Neurocritical Care Society guidelines, 365
 neurocritical care unit (NCCU), 355
 neurocritical care unit (NCCU) stroke
 patients
 airway management, 356–57
 analgesia, 357–58
 anti-coagulation, 360–61
 basilar artery (BA) occlusion, 367
 blood pressure (BP) management, 361
 body temperature management,
 361–62
 brain edema and raised ICP, 362–64
 conservative management of large or
 progressive ICH, 368–69
 deep vein thrombosis (DVT) prophylaxis,
 360
 definition of severe stroke, 355
 dysphagia management, 358–59
 feeding and swallowing problems,
 358–59
 fluid status, 359
 general principles of intensive care for
 stroke, 355–64
 glucose control, 359
 hemoglobin control, 359–60
 indications for transfer of stroke patients
 to the NCCU, 355–56
 infection control, 361
 intraventricular hemorrhage (IVH) in
 ICH, 370
 ischemic stroke from infective
 endocarditis, 367–68
 large hemispheric stroke (LHI), 365
 nutrition, 359
 peri-interventional care in stroke
 thrombectomy, 364–65
 sedation, 357–58
 seizures, 362
 space-occupying cerebellar stroke,
 365–67
 specific care for intracerebral hemorrhage
 (ICH), 368–70
 specific intensive care for acute ischemic
 stroke, 364–68
 surgical management of ICH, 369–70
 tracheostomy, 357
 ventilation, 357
 neurocysticercosis, 403
 neurofibromatosis, 197
 neurogenesis after stroke, 9
 NeuroLink system, 338
 neuromuscular electrical stimulation
 (NMES), 437
 neuronal plasticity and stroke recovery, 78
 neuroprotective therapies, 327–28
 pre- and post-conditioning of ischemia, 23
 neuroradiology. *See* imaging; multimodal
 imaging and specific imaging
 modalities
 neurorehabilitation
 aphasia, 440–41
 apraxia, 441–42
 case study, 426, 427, 432, 435, 438, 442
 cognition, 442
 constraint-induced movement therapy
 (CIMT), 435–36
 current approaches, 432–42
 electrical stimulation, 436–37

Index

- neurorehabilitation (*cont.*)
 electromechanical-assisted arm training, 437–38
 electromechanical-assisted gait training, 432–34
 gait training, 432–35
 hand-arm training methods, 435–38
 impairment-oriented therapy (IOT), 436
 improving sit-to-stand ability, 432
 improving upper limb function, 435–38
 mirror therapy, 436
 mobility, 432
 neglect, 442
 NMES, 437
 non-invasive brain stimulation (NIBS), 439–40
 physical fitness training after stroke, 439
 powered robotic exoskeletons, 434
 principles of stroke rehabilitation, 428–30
 repetitive transcranial magnetic stimulation (rTMS), 440
 somatosensory rehabilitation, 438–39
 speech and language therapy (SLT), 440–41
 strength training after stroke, 439
 TENS, 436–37
 transcranial direct current stimulation (tDCS), 439–40, 441
 treadmill training (with and without body support), 434
 upper motor neuron syndrome (UMNS), 430–32
 visual field defects, 442
 WHO definition of rehabilitation, 426
 neurosyphilis, 402–3
 neurovascular coupling, 12
 neurovascular unit
 pathology of ischemic injury, 9
 nicotine replacement therapy, 133, 134
 NINDS rtPA trial, 377, 379
 NINDS study, 315, 316
 NINDS-AIREN criteria, 387
 nitrendipine, 411
 nitric oxide (NO)
 effects in ischemia, 21
 nitric oxide (NO) synthase (NOS), 21
 nocturnal paroxysmal hemoglobinuria, 299
 NOGO-A protein expression, 22
 non-bacterial thrombotic endocarditis (NBTE), 190
 non-compaction (LVHT)
 relevance to stroke, 164–66
 non-contrast computed tomography (NCCT), 50–51
 non-cruoric emboli
 in young people and children, 300
 non-invasive brain stimulation (NIBS), 439–40
 non-vitamin K antagonist oral anti-coagulants (NOACs), 156
 NOAC-associated ICH, 226–27
 potential reversal agents, 226–27
 nortriptyline, 133
 NOTCH-1 receptor, 22
 NOTCH3 gene, 11, 296
 Nurses' Health Study, 130, 133
 NXY-059 free radical-trapping agent, 327
 obesity
 risk factor for stroke, 134–35
 obstructive sleep apnea (OSA)
 stroke risk factor, 145
 olivopontocerebellar atrophy
 differential diagnosis, 209
 omega 3 fatty acids consumption
 stroke risk and, 136–37
 ophthalmic artery, 169
 ophthalmopathy
 ischemic, 184
 optic nerve sheath diameter (ONSD)
 measurement, 104
 optical coherence tomography (OCT), 6
 oral anti-coagulant therapy. *See* anti-coagulant therapy
 oral contraceptives
 CVT risk, 6
 stroke risk, 300–1
 osmotic diuretics, 259
 outcome of stroke
 approaches to prediction, 68
 neuronal plasticity and, 78
 prognosis and prediction models, 427–28
 prognostic value of ultrasound, 102–3
 Oxford Vascular Study, 121
 Oxfordshire Community Stroke Project Subtype Classification (OCPS), 110, 169
 panarteritis nodosa, 1, 297
 papillary fibro-elastoma
 in young people and children, 295
 paradoxical embolism, 43, 162, 294
 paramedian arteries
 stroke syndromes, 178
 paraneoplastic vasculitis, 190
 paraproteinemia, 185
 Parinaud syndrome, 235, 239
 PATCH trial, 225
 patent foramen ovale (PFO)
 association with interatrioseptal aneurysm (IASA) in stroke patients, 295
 cardioembolic stroke risk, 43
 closure in stroke patients, 417–18
 in young people and children, 294–95
 paradoxical embolism, 162
 prevalence, 162
 relevance to stroke, 162–63
 right-to-left shunt detection, 103
 stroke risk, 162–63
 surgical or interventional closure, 162–63
 PC-Trial, 417
 PCSK9 inhibitors, 412
 PEARL trial, 140
 Penumbra Pivotal Stroke Trial, 342
 Penumbra System, 341–42
 percutaneous endoscopic gastrostomy (PEG), 358
 percutaneous transluminal balloon angioplasty (PTA), 336
 perfusion computed tomography (PCT), 51–53
 perfusion-weighted imaging (PWI), 16, 57–58
 arterial spin labeling (ASL), 58
 dynamic susceptibility contrast (DSC)-PWI, 57
 PWI/DWI mismatch, 58
 PWI/DWI mismatch studies, 27–29, 29
 perimesencephalic hemorrhage, 237–38
 peripartum
 amniotic emboli, 300
 cardiomyopathies related to, 295
 gas emboli, 300
 peroxynitrite, 21
 personality changes
 post-stroke, 277–78
 pH-weighted imaging (pHWI), 16
 pharmacogenetics, 11
 phenprocoumon, 217
 photoacoustic imaging (PAI), 6
 physical fitness training after stroke, 439
 physical inactivity
 risk factor for stroke, 135–36
 Physicians' Health Study, 216
 pioglitazone, 412
Plasmodium falciparum, 405
 POINT trial, 327
 polar artery
 stroke syndromes, 177–78
 pollution
 risk factor for stroke, 145–46
 polyarteritis nodosa, 190
 polycythemia, 299
 polycythemia vera, 185
 pontine hemorrhage, 5–6
 positron emission tomography (PET)
 functional and activation studies, 76–78
 imaging ischemic penumbra, 16
 quantifying ischemic tissue injury, 26–27
 positron emission tomography (PET)-tracers, 209–10
 post-conditioning of ischemia, 23
 posterior cerebral artery (PCA), 169
 cognitive effects of strokes, 203
 stroke syndromes, 176–77
 posterior choroidal artery (PChA)
 stroke syndromes, 178
 posterior circulation
 clinical distinction between anterior and posterior circulation strokes, 172–73
 description, 172
 low-flow stroke syndromes, 184–85
 recanalization techniques, 346–47
 stroke syndromes, 172–78
 ultrasound diagnosis of stenosis and occlusion, 96–97
 posterior communicating artery (PCoA), 169
 posterior inferior cerebellar artery (PICA)
 stroke syndromes, 173–74
 posterior reversible encephalopathy syndrome (PRES), 177
 post-irradiation cervical arteriopathies
 in young people and children, 296
 post-menopausal estrogen replacement therapy
 stroke risk and, 139–40
 post-partum cerebral angiopathy, 298

- post-stroke dementia (PSD). *See* dementia (post-stroke)
 post-stroke depression. *See* depression (post-stroke)
 post-stroke fatigue. *See* fatigue (post-stroke)
 post-stroke seizures. *See* seizures (post-stroke)
 post-traumatic stress disorder (PTSD)
 post-stroke, 276
 potassium intake
 stroke risk and, 138
 powered robotic exoskeletons, 434
 preconditioning of ischemia, 23
 PREDICT trial, 219
 prediction of irreversible tissue damage, 27
 PREDIMED trial, 139
 pregnancy
 after an ischemic stroke, 302–3
 cerebral venous thrombosis (CVT), 260–61
 choriocarcinoma, 300
 CVT risk, 6
 eclampsia, 298–99
 MRI contraindications, 54
 stroke risk, 301
 prevalence of stroke, 113–15
 prevention of stroke. *See also* secondary prevention
 early management of vascular risk, 146
 effects of environmental pollution, 145–46
 high-risk approach, 130
 lifestyle factors, 130–39
 primary angitis of the central nervous system, 190
 primary systemic vasculitis, 190
 PRINCIPLE study, 356
 PROACT II trial, 319, 335, 336
 PRoFESS study, 411, 414
 PROGRESS trial, 216, 411
 progressive supranuclear palsy
 differential diagnosis, 209
 prosopagnosia, 272
 prosthetic heart valves
 cardioembolic stroke risk, 42–43
 protein kinase R (PKR), 21
 protein synthesis
 inhibition by the ER stress response, 21–22
 prothrombotic state, 299
 prourokinase, 335
 proximal thrombectomy, 339–42
 pseudoseizures, 175
 psychotic disorders, 274–75
 PTX2 gene, 11
 puerperium
 cerebral venous thrombosis (CVT), 260–61
 CVT risk, 6
 reversible cerebral vasoconstriction syndrome (RCVS), 198
 pure motor hemiparesis, 179, 186
 pure motor hemiplegia, 46
 pure sensory stroke, 179
 putaminal hemorrhage, 5
 Qstroke algorithm, 122
 QT prolongation
 causes, 159
 definition, 159
 relevance to stroke, 159
 quality of life
 young stroke patients, 302
 racial risk factors for stroke, 119
 raloxifene, 140
 ramipril, 410
 ranitidine, 358
 RAPID® software, 58
 RASUNOA (Registry of Acute Stroke Under New Oral Anticoagulants), 226
 reactive oxygen species (ROS), 8, 13, 21, 22
 role in ischemic injury, 21
 recanalization
 aspiration and/or stent retriever thrombectomy, 345
 catheter angiography, 333–34
 digital subtraction angiography (DSA), 333–34
 distal branch occlusion, 349
 distal thrombectomy devices, 336–38
 first-generation mechanical treatment approaches, 336–39
 flat panel detector (FPD) technology, 334
 importance in acute stroke, 333
 percutaneous transluminal balloon angioplasty (PTA), 336
 pharmacological intra-arterial thrombolysis, 334–35
 posterior circulation, 347–48
 proximal thrombectomy, 339–42
 special techniques for particular situations, 347–49
 standards of practice and training curriculum, 349–51
 stent recanalization, 338–39
 stent retrievers, 342–45
 tandem occlusion of the anterior circulation, 348–49
 techniques, 315–26, 339–45
 thromboaspiration, 339–42
 thrombus disruption, 336
 Recklinghausen disease, 297
 recombinant Factor VIIa (rFVIIa) trials, 225
 recombinant tissue plasminogen activator (rtPA), 11, 50, 315–19, 333
 recurrent artery of Heubner, 171
 red (hemorrhagic) infarcts, 4–5
 REDUCE trial, 163, 418
 rehabilitation. *See also* neurorehabilitation
 acute phase, 426–27
 assessment, 428
 early mobilization, 426–27
 early rehabilitation, 312–13
 interdisciplinary team, 426
 principles of stroke rehabilitation, 428–30
 process of individual rehabilitation, 426
 prognosis and prediction models, 427–28
 stages of, 426
 WHO definition, 426
 WHO international classification of functioning (ICF), 428
 RE-LY trial, 416
 Rendu-Osler-Weber disease, 295
 repetitive transcranial magnetic stimulation (rTMS), 79, 439, 440
 combined with activated imaging, 81–83
 RESPECT trial, 163, 417, 418
 restrictive cardiomyopathy
 relevance to stroke, 164
 RETRACE study, 226, 369
 REVASCAT trial, 345
 reversible cerebral vasoconstriction syndrome (RCVS), 198
 rheumatoid arthritis, 1
 ribosomes, 8, 21
 right-to-left shunt
 ultrasound detection, 103
 risk factors for stroke
 alcohol consumption, 134
 approach to prevention, 130
 assessing the causal significance of, 124
 atrial fibrillation (AF), 144–45
 cigarette smoking, 132–34
 classification, 118–19
 diabetes mellitus, 142
 dietary factors, 136–39
 dyslipidemia, 142–44
 familial risk, 119
 hypertension, 140–41
 in young people and children, 300–1
 lifestyle factors, 130–39
 modifiable and non-modifiable types, 118–19
 MONICA Stroke Study (WHO), 119–20
 new risk factors, 124
 obesity, 134–35
 obstructive sleep apnea (OSA), 145
 physical inactivity, 135–36
 pollution, 145–46
 post-menopausal estrogen replacement therapy, 139–40
 potentially modifiable risk factors, 130
 predicting stroke in the general population, 121–24
 racial or ethnic risk, 119
 raised cholesterol levels, 142–44
 transient ischemic attack (TIA), 120–21
 vascular risk factors and cognitive decline, 146
 rivaroxaban, 144, 145, 156, 226, 415, 416
 potential reversal agents, 226–27
 Robin Hood syndrome, 13
 Rochester study
 risk of AD after stroke, 285
 ROCKET AF trial, 416
 rotational vertebral artery occlusion (RVAO)
 stroke syndromes, 184
 RUTH trial, 140
Salmonella spp., 404
 salt intake
 stroke risk and, 137–38
 SAMMPRIS trial, 420
 sarcoidosis, 297
 SARIS trial, 338
 SASS (study), 384

Index

- SCAST study, 378
 secondary prevention
 after ischemic stroke in young adults, 303
 aim of, 410
 anti-coagulation in cerebral ischemia due to cardiac embolism, 415–17
 anti-coagulation in cerebral ischemia of non-cardiac origin, 418–19
 anti-hypertensive therapy, 410–11
 anti-platelet therapy, 412–15
 blood glucose management, 412
 carotid artery stenting, 419–20
 carotid endarterectomy, 419–20
 effects of hormone replacement therapy after menopause, 412
 in the ED or stroke unit, 312
 intracranial stenosis treatment, 420–21
 management of cholesterol levels, 411–12
 management of diabetes mellitus, 412
 management of insulin resistance, 412
 patent foramen ovale (PFO) closure, 417–18
 risk of stroke recurrence, 410
 statin therapy, 411–12
 treatment of risk factors, 410–12
 vitamin supplementation, 412
 sedation
 ICU stroke patients, 357–58
 seizures (post-stroke)
 in ICU stroke patients, 362
 management, 383–85
 selective estrogen receptor modulators (SERMs), 139–40
 selective serotonin reuptake inhibitors (SSRIs), 273
 semantic system, 264
 sensorimotor stroke, 179
 septic coagulopathy, 190
 septic CVT, 6, 250–51, 252
 diagnostic workup, 252–56
 laboratory markers, 255–56
 therapy, 256–60
 septic endarteritis, 190
 SETPOINT2 trial, 357
 sickle cell anemia, 185
 sickle cell disease, 197, 299
 Sicut syndrome, 300
 SIK2 pathway, 22
 silent lesions
 dementia associated with, 282
 dementia risk related to pre-existing infarcts, 286
 silent lacunar infarcts, 46
 simvastatin, 411
 single nucleotide polymorphisms (SNPs), 11
 SITS register, 316
 SITS study, 377
 sixth nerve palsy, 46, 235
 Sjögren's syndrome, 1, 190, 297
 small-vessel disease (SVD), 1, 3
 as subtype of vascular dementia, 202–3
 brain atrophy, 286
 cause of ischemic stroke, 44–46
 cerebral amyloid angiopathy (CAA), 3
 classification of causes, 202
 cognitive and/or behavioral effects, 203
 damage to the cerebral microcirculation, 203
 definition, 202
 development of ICH, 217
 diagnosis, 202
 features of this group of diseases, 210
 leukoaraiosis, 204
 lipohyalinosis, 217
 miliary aneurysms, 3
 MRI markers, 204–5
 status cribrosus (état criblé), 3
 status lacunaris (lacunar state), 3
 white matter hyperintensities, 203, 204
 small-vessel occlusion
 in young people and children, 296
 smartphone apps
 stroke risk calculators, 122
 smoking
 risk factor for ICH, 216
 risk factor for stroke, 132–34
 Sneddon syndrome, 1, 190
 in young people and children, 298
 SOCRATES study, 415
 sodium intake
 stroke risk and, 137–38
 SOLUMBRA technique, 345, 347
 somatoparaphrenia, 274
 somatosensory deficits
 functional imaging of recovery, 78–79
 somatosensory rehabilitation, 438–39
 SonoVue, 101
 SPARCL trial, 217, 411
 spatial neglect. *See* neglect
 speech and language therapy (SLT), 440–41
 spherocytosis, 185
 SPIRIT trial, 418
 spot sign on CT, 218–19
 SPOTLIGHT trial, 225
 SPRINT trial, 141
 SPS3 trial, 411
 SS-TOAST classification, 169
 SSylvia trial, 338
 STandards for ReportIng Vascular changes on nEuroimaging (STRIVE), 204
Staphylococcus aureus, 190, 398, 404, 406
Staphylococcus spp., 399
 State-Trait Anger Expression Inventory-2™ (STAXI-2™), 274
 statins
 ICH risk and, 216–17
 therapy for stroke patients, 411–12
 status cribrosus (état criblé), 3
 status epilepticus, 362
 status lacunaris (lacunar state), 3
 steal phenomena, 12, 13
 stent recanalization, 338–39
 stent retrievers, 342–45
 STICH trial, 223, 369
 STICH II trial, 223, 369
 STOP Stroke study, 73
 STOPIT trial, 225
 strength training after stroke, 439
Streptococcus pneumoniae, 398, 406
Streptococcus spp., 399, 404
 stroke
 animal models, 9–11
 cellular pathology of ischemic injury, 6–9
 clinical application of experimental results, 26–29
 coexistence with coronary heart disease, 159
 definition, 109–10
 energy requirements of brain tissue, 14
 frequency of different causes, 3
 functional and structural viability thresholds of ischemia, 14–16
 genetic factors, 11
 imaging ischemic penumbra, 16
 ischemic penumbra concept, 13–14
 life-changing effects, 68
 neuropathology, 1–9
 pathophysiology, 9–29
 pre- and post-conditioning of ischemia, 23
 predicting stroke in the general population, 121–24
 prehospital care and referral, 307–8
 regeneration of neurons, 9
 relationship with dementia, 282
 repair, 9
 secondary complications, 23–24
 subtypes, 110
 temporal evolution, 16–19
 therapeutic window, 24–26
 Stroke Alarm at the ED, 308
 stroke recurrence
 influence of post-stroke dementia, 288
 risk in patients with PFO/IASA association, 295
 stroke risk assessment tools, 122–24
 stroke risk calculators
 smartphone apps, 122
 Stroke Riskometer app, 122
 stroke syndromes
 agitation as presenting symptom, 188
 akinesia, 189–90
 amnesia, 187–88
 anterior cerebral artery (ACA), 171
 anterior choroidal artery (AChA), 171–72
 anterior circulation, 169–72
 anterior circulation low-flow syndromes, 182–84
 anterior inferior cerebellar artery (AICA), 174
 basilar artery (BA), 175–76, 186–87
 bilateral blindness, 186–87
 borderzone infarcts, 179–80
 boundary zone infarcts, 182–83
 capsular warning syndrome, 186
 classification systems, 169
 clinical distinction between anterior and posterior circulation strokes, 172–73
 clinical importance of recognition, 169
 common syndromes, 169–80
 delirium as presenting symptom, 188
 drop attacks, 184
 focal paresis, 190
 hereditary causes of stroke, 193–95
 internal carotid artery (ICA), 172
 involuntary movement, 189–90
 ischemic ophthalmopathy, 184

- isolated cranial nerve palsy, 189
- lacunar stroke syndromes, 179
- less common syndromes, 182–98
- limb-shaking TIA, 183
- low-flow strokes, 182–85
- manifestations of systemic disease, 190–92
- middle cerebral artery (MCA), 170–71
- posterior cerebral artery (PCA), 176–77
- posterior circulation, 172–78
- posterior circulation low-flow syndromes, 184–85
- posterior inferior cerebellar artery (PICA), 173–74
- reduced vigilance or coma as the leading symptom, 188
- related to bacterial meningeal infections, 192–93
- related to CADASIL, 193–94
- related to connective tissue disease, 190–92
- related to endocarditis (infective and non-infective), 190
- related to Fabry disease, 194–95
- related to inflammatory vasculopathies, 190–92
- related to MELAS, 195
- related to meningeal infections, 192–93
- related to migraine, 197–98
- related to Moyamoya, 197
- related to syphilitic meningovascularitis, 193
- related to tuberculous meningitis, 192–93
- related to varicella zoster virus (VZV) vasculopathy, 192
- related to virus and bacterial infections, 192–93
- reversible cerebral vasoconstriction syndrome (RCVS), 198
- rotational vertebral artery occlusion (RVAO), 184
- subclavian artery, 184–85
- superior cerebellar artery (SCA), 174–75
- thalamus, 177–78
- uncommon causes, 190–98
- uncommon clinical presentations, 186–90
- uncommon mechanism (low flow), 182–85
- unusual presentations of arterial dissection, 196–97
- vertebral artery (VA), 173–74, 184–85
- vertebrobasilar ischemia, 184
- watershed infarcts, 179–80
- stroke therapy
 - pharmacogenetics, 11
- stroke unit
 - acute therapies, 307
 - acute treatment, 311
 - clinical assessment, 310
 - diagnostic workup, 310–11
 - early activities, 309–10
 - early rehabilitation, 312–13
 - elevated intracranial pressure management, 311–12
 - ESO criteria for facilities and organization, 309
 - features of stroke unit care, 308–9
 - future developments in stroke management, 313
 - general management, 311
 - monitoring, 311
 - prehospital care and referral, 307–8
 - prevention and treatment of complications, 311
 - role in the chain of recovery, 307
 - secondary prevention, 312
- structural imaging, 69–73
 - computed tomography (CT), 69–71
 - magnetic resonance imaging (MRI), 71–73
- subarachnoid hemorrhage (SAH)
 - ancillary investigations for diagnosing aneurysms, 236–37
 - ancillary investigations for diagnosing SAH, 235–36
 - aneurysmal SAH, 233–34
 - clinical long-term outcomes, 243–44
 - definition, 233
 - delayed cerebral ischemia prevention or treatment, 241–43
 - diagnosis, 234–37
 - epidemiology, 233–34
 - general management, 240–41
 - initial assessment, 238–39
 - long-term outcome, 243–44
 - perimesencephalic hemorrhage, 237–38
 - prevalence of intracranial aneurysms, 233
 - prevention of rebleeding, 243
 - prognosis, 238
 - risk factors for intracranial aneurysms, 233
 - risk of cardiovascular events, 244
 - risk of new episodes, 244
 - symptoms and signs, 234–35
 - treatment, 238–43
- subclavian artery
 - stroke syndromes, 184–85
 - ultrasound identification of stenosis, 94–95
- subclavian steal syndrome, 184–85
- subcortical ischemic vascular disease (SIVD)
 - differential diagnosis, 208
- suicidal ideation and behavior, 277
- superior cerebellar artery (SCA)
 - stroke syndromes, 174–75
- Susac syndrome, 300
- susceptibility-weighted imaging (SWI)
 - intracerebral hemorrhage (ICH), 58–59
- swallowing-provocation-test (SPT), 358
- Sweden
 - National Stroke Register (Riks-Stroke), 117
- Sweet syndrome, 300
- SWIFT PRIME trial, 345
- SWIFT study, 344
- SWITCH trial, 224
- Sylvius, Jacobus, 170
- Synthesis trial, 337
- syphilitic meningovascularitis
 - stroke syndromes related to, 193
- systemic lupus erythematosus (SLE), 1, 190, 192, 260, 297, 299
- tachycardia
 - causes, 158–59
 - definition, 158
 - practical approach to stroke patients with, 158
 - relevance to stroke, 158–59
 - symptoms, 159
- Taenia solium*, 403
- Takayasu's arteritis, 1, 184, 190, 297
- Takotsubo cardiomyopathy
 - relevance to stroke, 164
- tamoxifen, 140
- Tardieu Scale, 431
- tau protein deposition
 - imaging, 210
- tea consumption
 - stroke risk and, 139
- Tel Aviv stroke register, 376
- telmisartan, 411
- temperature. *See* body temperature
- tenecteplase, 318, 319
- TENS, 436–37
- territorial infarcts, 3, 4
- Terson's syndrome, 235
- terutroban, 415
- thalamic hand, 178
- thalamic hemorrhage, 5
- thalamogeniculate arteries
 - stroke syndromes, 178
- thalamus
 - stroke syndromes, 177–78
 - vascularization, 177–78
- therapeutic window for stroke, 24–26
- THERAPY trial, 342
- THIS trial, 380, 381
- thromboaspiration, 339–42
- thrombectomy
 - peri-interventional care, 364–65
 - use of animal model of clot embolism, 11
- thromboangiitis obliterans, 297
- thrombocytopenia, 299
- thromboembolism, 2–3
 - risk after heart valve surgery, 161
- thrombolysis
 - cerebral venous thrombosis, 258
 - ultrasound-accelerated thrombolysis, 103
 - use of animal model of clot embolism, 11
- Thrombolysis in Brain Ischemia (TIBI)
 - flow-grading system, 102
- Thrombolysis in Cerebral Ischemia (TICI), 341
- thrombophilia
 - acquired, 299
 - congenital, 299
- thrombotic thrombocytopenic purpura, 299
- thrombus
 - disruption and fragmentation, 336
 - ultrasound identification of free-floating thrombus, 95
- ticagrelor, 412, 414, 415
- tigrolysis, 8
- tissue acidosis
 - effects on blood flow regulation, 12
- TOAST classification, 38, 110, 169, 294
- Todd's paresis, 318
- Toll-like receptors 2 and 4, 22

Index

- TORC1 protein expression, 22
torsades de pointes, 159
Toxoplasma gondii, 405
toxoplasmosis
 ischemic lesions mimicking stroke, 405
tracheostomy, 357
TRAIT profile, 58
tranexamic acid, 225
transcallosal inhibition, 79
transcranial alternating current stimulation (tACS), 439
transcranial color-coded consensus (TCCS) group, 103
transcranial color-coded duplex sonography (TCCD), 97
transcranial direct current stimulation (tDCS), 439–40, 441
transcranial Doppler (TCD), 95
transcranial magnetic stimulation (TMS), 78
transcranial pulsed ultrasound (TPU), 439
transesophageal echocardiography (TEE), 162, 294
transient ischemic attack (TIA), 172
 capsular warning syndrome, 186
 limb-shaking TIA, 172, 183
 predicting stroke risk, 120–21
transthoracic echocardiography (TTE), 294
treadmill training (with and without body support), 434
treatment decision-making
 based on multimodal imaging, 60
treatment efficacy
 surrogate markers for, 29
Treponema pallidum, 193, 403
TREVO 2 study, 345
trifusil, 415
Trypanosoma cruzi, 401
tuberculosis, 1
tuberculous meningitis, 402
 stroke syndromes related to, 192–93
tuberothalamic artery
 stroke syndromes, 177–78
TULIA apraxia screen, 442
TUNEL assay, 22
tunica media
 calcification, 1

ulcerative rectocolitis, 297
ultrasound
 applications in acute stroke, 90–91
 basilar artery stenosis and occlusion, 97
 color flow Doppler, 91
 contrast agents, 101
 detection of arterial resistance, 104
 diagnosis of intracranial stenosis and occlusion, 95–96
 diagnosis of stenosis and occlusion in the posterior circulation, 96–97
 diagnostic brain perfusion imaging in acute stroke, 101
 Doppler ultrasound, 90–91
 emboli monitoring in acute stroke, 100–1
 evaluation of carotid artery stenosis, 90–91
 fast-track neurovascular examination, 97–100
 free-floating thrombus, 95
 identification and classification of ICA stenosis, 91–94
 MCA occlusion, 96
 MCA stenosis, 96
 midline shift detection, 104
 monitoring of microembolic signs (MES), 100–1
 negative predictive value calculation, 90
 optic nerve sheath diameter (ONSD) measurement, 104
 positive predictive value calculation, 90
 prognostic value in acute stroke, 102–3
 promising ancillary techniques for acute stroke, 103–4
 real-time visualization of MCA infarction, 101–2
 right-to-left shunt detection, 103
 sensitivity and specificity calculations, 90
 subclavian artery stenosis, 94–95
 transcranial Doppler (TCD), 95
 vertebral artery stenosis, 94–95
 ultrasound-accelerated thrombolysis, 103
 unfolded protein response (UPR), 21, 22, 23
 Union Européen des Médecins Spécialistes (UEMS), 350
 upper motor neurone syndrome (UMNS)
 adaptive features, 431–32
 negative features, 431
 neurorehabilitation, 430–32
 positive features, 430–31
 urinary tract infections (UTI)
 post-stroke, 406
 urokinase, 335, 347

valvular heart disease
 relevance to stroke, 160–62
varenicline, 134
varicella zoster virus (VZV) vasculopathy, 403–4
 stroke syndromes related to, 192
vascular cognitive decline
 distinction from vascular dementia, 202
vascular cognitive impairment, 1
 differential diagnosis, 205–8
vascular dementia, 1
 cognitive effects of strokes, 203
 computed tomography (CT), 203–4
 definition, 282
 differential diagnosis, 205–8, 209–10
 differential diagnosis between dementias with FDG PET, 208–9
 distinction from vascular cognitive decline, 202
 imaging accumulation of pathologic proteins, 209–10
 imaging synaptic transmission, 209–10
 location of causal strokes, 203
 magnetic resonance imaging (MRI), 204–5
 main neuroimaging patterns, 202
 microhemorrhages, 204–5
 molecular diagnostic imaging, 205–8
 neuroimaging approaches, 203–5

prevalence of vascular etiologies, 202
small-vessel disease as subtype, 202–3
vascular risk factors for stroke
 association with cognitive decline, 146
vasculitis
 caused by infectious diseases, 403–4
 primary vasculitis of the central nervous system, 298
 secondary vasculitis in the context of infectious disorder, 297
 secondary vasculitis in the context of systemic disorder, 297
vegetable intake
 stroke risk and, 136
vertebral artery (VA), 172
 stroke syndromes, 173–74, 184–85
 ultrasound identification of stenosis, 94–95
vertebrobasilar circulation. *See* posterior circulation
vertebrobasilar ischemia
 symptoms, 184
vigilance, reduced
 as stroke symptom, 188
viridans group streptococci, 398, 404
virus infections
 stroke syndromes related to, 192–93
VISP study, 412
visual agnosia, 271–72
visual field defects
 rehabilitation after stroke, 442
vitamin K antagonist (VKA)-associated ICH, 226
vitamin K antagonists (VKAs), 156
vitamin supplementation for stroke patients, 412
voraxapar, 415

WAKE-UP study, 56
Waldenström's macroglobulinemia, 185
Wallenberg, Adolf, 174
Wallenberg syndrome, 173, 174
WARCEF trial, 164, 417
warfarin, 144, 217, 415, 416
WARSS trial, 419
WASID-II study, 420
watershed infarcts
 stroke syndromes, 179–80
watershed strokes, 203
Wegener's granulomatosis, 1, 190
Wernicke's aphasia, 171, 274
whole grain intake
 stroke risk and, 136
Wingspan system, 338
Women's Health Initiative (WHI), 139
Women's Health Study, 216
World Health Organization (WHO)
 definition of rehabilitation, 426
 international classification of functioning (ICF), 428
 MONICA Stroke Study, 116, 119–20

young people/children
 acute management of stroke, 301
 atrial fibrillation (AF), 294
 CADASIL, 296
 causes of ischemic strokes, 293–300

cardioembolism, 294–95	intracranial dissection, 297	post-irradiation cervical arteriopathies, 296
cerebral ischemia of undetermined and unknown causes, 300	lacunar infarcts, 296	primary vasculitis of the CNS, 298
hematological disease, 299	lipohyalinosis of the deep perforators, 296	risk factors for stroke, 300–1
large artery disease, 296–99	mitral valve prolapse, 295	secondary prevention after ischemic stroke in young adults, 303
large-vessel atherosclerosis, 294	Moyamoya, 297	small-vessel occlusion, 296
metabolic disorders, 299–300	non-cruoric emboli, 300	Sneddon syndrome, 298
rare causes of undetermined mechanism, 300	outcome of stroke, 301–3	specificities of ischemic strokes in, 292
cervical artery dissection, 296	epilepsy, 302	stroke recurrence risk with PFO/IASA association, 295
cervical fibromuscular dysplasia of the cervical arteries, 296–97	mortality rate, 301–2	vasculitis related to infectious disorder, 297
diagnostic workup, 292–93	pregnancy after an ischemic stroke, 302–3	vasculitis related to systemic disorder, 297
epidemiology of strokes, 292	quality of life, 302	
incidence of strokes, 292	recurrent vascular events (stroke or coronary), 302	
infective endocarditis, 294	specificities of children, 303	
interatrioseptal aneurysm (IASA), 295	papillary fibro-elastoma, 295	ZFHx3 gene, 11
intracardiac myxoma, 295	patent foramen ovale (PFO), 294–95	zinc
		effects in ischemia, 21